drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T)
drug_description
Autologous anti-CD19 CAR T-cell therapy with CD3ζ/CD28 costimulation used to treat relapsed/refractory B-cell lymphomas.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Axicabtagene ciloleucel
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express an anti‑CD19 chimeric antigen receptor with CD28 costimulation and CD3ζ signaling. Upon binding CD19 on malignant B cells, the CAR activates T-cell cytotoxicity, proliferation, and cytokine release, leading to targeted lysis of CD19-positive tumor cells.
drug_name
Axicabtagene ciloleucel (axi-cel)
nct_id_drug_ref
NCT05675982